Amy is a healthcare investor and managing partner of the LS Polaris Innovation Fund. She is a highly respected leader in the biotech and pharmaceutical industries. Amy joined Polaris Partners in 2014, bringing her commercial expertise to the startup biotech community. Upon joining Polaris, she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company acquired by Eagle Pharmaceuticals in 2016. She is currently managing partner of the LS Polaris Innovation Fund and represents Polaris investments as executive chair of SQZ Biotech and Olivo Labs, is the active CEO and co-founder of Lyndra, and is an active advisor to several post-doc students. She is also a director of Quentis and Kallyope.
Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.
Schulman has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.
She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.